Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lixte Biotechnology Holdings ( (LIXT) ) has shared an announcement.
On March 18, 2026, Lixte Biotechnology Holdings, Inc. amended the employment agreement of Chief Executive Officer Geordan Pursglove, originally signed on June 16, 2025, to increase his annual base salary from $240,000 to $360,000, retroactive to January 1, 2026. The pay adjustment, approved by the company’s Compensation Committee and Board of Directors, underscores the board’s support for its top executive and may signal confidence in current leadership as Lixte navigates its strategic and operational objectives.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a biopharmaceutical company focused on developing innovative cancer therapies and related biomedical technologies. The company operates in the biotechnology sector, targeting oncology markets with a strategy centered on advancing its drug candidates and strengthening leadership to support clinical and corporate milestones.
Average Trading Volume: 66,761
Technical Sentiment Signal: Sell
Current Market Cap: $23.32M
For an in-depth examination of LIXT stock, go to TipRanks’ Overview page.